Skip Navigation
Search Menu
Find a Doctor


Photo of Dr. Matthias Holdhoff

Matthias Holdhoff, M.D., Ph.D.

Assistant Professor of Oncology

Male  | Languages: English, French, German

Appointment Phone


Main Location

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-7683 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »


  • Assistant Professor of Oncology
  • Assistant Professor of Neurosurgery
  • Joint Appointment in Medicine

Centers & Institutes


  • Medicine
  • Neurosurgery
  • Oncology - Brain Cancer
  • Medicine at Sibley Memorial Hospital


Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964

401 N. Broadway
Baltimore, MD 21231 map
Phone: 410-955-8964

Sibley Memorial Hospital

5255 Loughboro Road NW
Washington, DC 20016 map
Phone: 202-660-6500


Brain Cancer, Brain Tumors, Medical Oncology , Neuro-Oncology

Research Interests

Translational Research in Neuro-Oncology; Clinical Trials (therapeutic and diagnostic); Brain Tumors


Dr. Matthias Holdhoff trained as a clinical translational investigator for the last three years under Stuart Grossman, M.D., Luis Diaz, M.D., and Bert Vogelstein, M.D. He will continue his translational brain tumor research in the Kimmel Cancer Center's Brain Cancer program and the Ludwig Center for Cancer Genetics and Therapeutics. Dr. Holdhoff's primary focus will be the development of blood-based tumor markers for patients with malignant gliomas and primary CNS lymphomas and novel translational clinical trials. 

Dr. Holdhoff received his medical degree in 2003 from Freie Universitt Berlin. He received his doctorate degree (Ph. D.) from Charit University Medicine Berlin magna cum laude. He completed his internal medicine training at Johns Hopkins Bayview Medical Center and he became board-certified in internal medicine in 2007. Dr. Holdhoff completed his medical oncology and neuro-oncology training at Johns Hopkins at the end of June 2010 and has already received ABIM board certification in Medical Oncology. He was given the 2010 ASCO Young Investigator Award for his proposal on the development of a blood-based biomarker for malignant gliomas. 

Dr. Holdhoff's position will actively link the Brain Cancer program and the Ludwig Center, thereby promoting a translational research exchange between the two groups. more

    Additional Information

  • Education +


    • Freie Universitat Berlin / MD (2003)


    • Johns Hopkins Bayview Medical Center / Internal Medicine (2007)


    • Johns Hopkins University School of Medicine / Oncology (2010)


    • American Board of Internal Medicine / Internal Medicine (2007, 2017)
    • American Board of Internal Medicine / Oncology (2009, 2019)
  • Research & Publications +

    Selected Publications

    Dr. Holdhoff's research is focused on translational research projects and clinical trials in neuro-oncology. As a member of the Brain Cancer Program and the Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins, he heads a working group for the development of blood-based biomarkers in malignant gliomas. Dr. Holdhoff graduated from medical school at Freie Universitt Berlin and he received his doctorate degree (German PhD equivalent) at Charit University Medicine Berlin. After internal medicine training at Johns Hopkins Bayview Medical Center he completed his medical oncology fellowship and subspecialty training in neuro-oncology at the Sidney Kimmel Comprehensive Cancer Center. Dr. Holdhoff is board certified in internal medicine and medical oncology and he has a clinic for patients with primary brain tumors, CNS lymphomas and other malignancies of the central nervous system.

    Journal Citations
    Holdhoff M, Supko JG, Gallia GL, Hann CL, Bonekamp D, Ye X, Cao B, Olivi A, Grossman SA. Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. J. Neurooncol 2010; 97: 241-5 (Epub ahead of print Sept 19, 2009).
    Holdhoff M, Schmidt K, Donehower R, Diaz LA, Jr. Analysis of Circulating Tumor DNA to Confirm Somatic KRAS Mutations. J Natl Cancer Inst 2009; 101: 1284-5.
    Holdhoff M, Parsons DW, Diaz LA, Jr. Mutations of IDH1 and IDH2 are not detected in brain metastases of colorectal cancer. J Neurooncol 2009; 94: 297 (Epub ahead of print April 7).
    Holdhoff M, Wung PK, Petronis JD, Couzi R. Persistent positron emission tomography-positive liver lesions after successful chemotherapy in mediastinal seminoma. J Clin Oncol. 2007; 25: 2482-4.
    Holdhoff M, Kreuzer KA, Appelt C, Scholz R, Na IK, Hildebrandt B, Riess H, Jordan A, Schmidt CA, Van Etten RA, Drken B, le Coutre P. Radiosensitization of a human glioblastoma cell line by imatinib mesylate through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis 2005; 34: 181-185.
    le Coutre P, Kreuzer KA, Na IK, Schwarz M, Lupberger J, Holdhoff M, Baskaynak G, Gschaidmeier H, Platzbecker U, Ehninger G, Prejzner W, Huhn D, Schmidt CA: Imatinib in Philadelphia chromosome positive chronic phase CML patients: molecular and cytogenetic response rates and prediction of clinical outcome. Am J Hematol 2003; 73: 249-255.
    le Coutre P, Kreuzer KA, Na IK, Lupberger J, Holdhoff M, Appelt, C, Schwarz M, Mller C, Gambacorti-Passerini C, Platzbecker U, Bonnet R, Ehninger G, Schmidt CA: Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukaemia during the first 13 weeks of therapy with STI571. Blood Cells Mol Dis 2002; 28: 75-85.
  • Academic Affiliations & Courses +
  • Activities & Honors +
  • Videos & Media +
Is This You? Edit Profile